Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults

NCT07513168 on ClinicalTrials.gov · last registry update 2026-04-06

Recruiting now, toward 60 participants. Its estimated completion date, 30 August 2026, has passed with no update to the record. Primary outcome, as filed: Percentage Change in Body Weight. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Asian Institute Of Medical Sciences
Sponsor type: Other
Enrollment: 60
Started: 2025-08-01
Primary completion: 2026-08-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage Change in Body Weight

Conditions studied

Obesity · Weight Reduction · Cardiometabolic Risk Factors

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.